Kishan S Parikh1,2, Jonathan P Piccini3. 1. Duke Clinical Research Institute, Durham, NC, USA. kishan.parikh@duke.edu. 2. Duke University Medical Center, DUMC 3428, Durham, NC, 27710, USA. kishan.parikh@duke.edu. 3. Duke Clinical Research Institute, Durham, NC, USA.
Abstract
PURPOSE OF REVIEW: We explore the pharmacogenomics of the beta-blocker bucindolol by discussing relevant beta-1 adrenergic receptor (ADRB1) polymorphisms and recent beta-blocker studies. Through this, we will understand how bucindolol may help patients with atrial fibrillation and heart failure with reduced ejection fraction (AF-HFrEF), which carries poor prognosis. RECENT FINDINGS: Retrospective study of the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training trial revealed the interaction between the optimal beta-blocker dose and the ADRB1 Arg389 genotype for HFrEF clinical outcomes. Further, a combinatorial genotype analysis in the Beta-Blocker Evaluation of Survival Trial showed that the Arg389Arg genotype, but not the Gly carrier, was associated with 40% lower mortality risk with bucindolol. Finally, the AF-HFrEF subgroup with the ADRB1 Arg389Arg genotype had greater heart rate reduction and suggestion for mortality benefit. Therapeutic response to beta-blockers varies by beta-blocker mechanism, ADRB1 Arg389 genotype, and clinical setting (AF, HFrEF, AF-HFrEF). The ongoing trial A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure prospectively identifies AF-HFrEF patients with favorable genotype for bucindolol to prevent AF recurrence.
PURPOSE OF REVIEW: We explore the pharmacogenomics of the beta-blocker bucindolol by discussing relevant beta-1 adrenergic receptor (ADRB1) polymorphisms and recent beta-blocker studies. Through this, we will understand how bucindolol may help patients with atrial fibrillation and heart failure with reduced ejection fraction (AF-HFrEF), which carries poor prognosis. RECENT FINDINGS: Retrospective study of the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training trial revealed the interaction between the optimal beta-blocker dose and the ADRB1Arg389 genotype for HFrEF clinical outcomes. Further, a combinatorial genotype analysis in the Beta-Blocker Evaluation of Survival Trial showed that the Arg389Arg genotype, but not the Gly carrier, was associated with 40% lower mortality risk with bucindolol. Finally, the AF-HFrEF subgroup with the ADRB1 Arg389Arg genotype had greater heart rate reduction and suggestion for mortality benefit. Therapeutic response to beta-blockers varies by beta-blocker mechanism, ADRB1Arg389 genotype, and clinical setting (AF, HFrEF, AF-HFrEF). The ongoing trial A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure prospectively identifies AF-HFrEFpatients with favorable genotype for bucindolol to prevent AF recurrence.
Authors: Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245
Authors: Julia Cadrin-Tourigny; Azadeh Shohoudi; Denis Roy; Mario Talajic; Rafik Tadros; Blandine Mondésert; Katia Dyrda; Léna Rivard; Jason G Andrade; Laurent Macle; Peter G Guerra; Bernard Thibault; Marc Dubuc; Paul Khairy Journal: JACC Heart Fail Date: 2017-01-11 Impact factor: 12.035
Authors: Janina M Jeff; Brian S Donahue; Kristin Brown-Gentry; Dan M Roden; Dana C Crawford; C Michael Stein; Daniel Kurnik Journal: Am Heart J Date: 2013-10-17 Impact factor: 4.749
Authors: T Rau; H-D Düngen; F Edelmann; F Waagstein; M Lainščak; S Dimković; S Apostolović; A N Nešković; W Haverkamp; G Gelbrich; T Eschenhagen Journal: Clin Pharmacol Ther Date: 2012-05-23 Impact factor: 6.875
Authors: Ryan G Aleong; William H Sauer; Gordon Davis; Guinevere A Murphy; J David Port; Inder S Anand; Mona Fiuzat; Christopher M O'Connor; William T Abraham; Stephen B Liggett; Michael R Bristow Journal: JACC Heart Fail Date: 2013-08 Impact factor: 12.035
Authors: Kersten M Small; Lynne E Wagoner; Albert M Levin; Sharon L R Kardia; Stephen B Liggett Journal: N Engl J Med Date: 2002-10-10 Impact factor: 91.245
Authors: C W Yancy; M B Fowler; W S Colucci; E M Gilbert; M R Bristow; J N Cohn; M A Lukas; S T Young; M Packer Journal: N Engl J Med Date: 2001-05-03 Impact factor: 91.245